Advertisement
Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
113 days ago
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
430 days ago
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
542 days ago
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
898 days ago
European Shares Seen Mostly Lower Before US Inflation Data
European stocks may open broadly lower on Friday as the prospect of a peace agreement between Russia and Ukraine waned and focus shifted to a key U.S. inflation reading due later in the day that could provide additional clues on the Federal Reserve's rate outlook.
RTTNews
|
1h 21min ago
Sensex, Nifty Struggle For Direction In Early Trade
Indian shares were little changed on Friday, giving up early gains amid mounting concerns about the impact of U.S. tariffs on Indian goods.
RTTNews
|
2h 28min ago
Australian Market Swings To Modest Gains In Mid-market
The Australian stock market is swinging to modest gains in mid-market moves on Friday after opening in the red, extending the gains in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying below the 9,000 mark, with gains in energy and technology stocks partially offset by weakness in mining and financial stocks.
RTTNews
|
3h 25min ago
Asian Markets Mixed Amid Caution Trades
Asian stock markets are mixed on Friday, following the broadly positive cues from Wall Street overnight, ahead of the release of key U.S. inflation data later in the day that could impact the outlook for interest rates. Traders also digested highly anticipated earnings news from Nvidia, with the AI darling and market leader reporting second-quarter results that largely exceeded expectations.
RTTNews
|
3h 54min ago
